Topoisomerases can manage DNA's topological state in the nuclear to facilitate the replication, recombination, transcription and repair of DNA by separating the two strands of the helix temporarily. There are 2 types of DNA topoisomerases which are type I topoisomerase and type II topoisomerase. [show the full text]
Topoisomerase Inibitori (Topoisomerase Inhibitors)
Altro DNA Damage/DNA Repair Inibitori
| N. Cat. | Nome del prodotto | Informazioni | Citazioni di utilizzo del prodotto | Validazioni del prodotto |
|---|---|---|---|---|
| E2516 | Doxorubicin | L'adriamicina (Doxorubicin, Hydroxydaunorubicin), un antibiotico antraciclinico citotossico, è un agente chemioterapico antitumorale, inibisce la topoisomerase II con un IC50 di 2,67 μM, bloccando così la replicazione del DNA e inducendo l'apoptosi. |
|
|
| S1198 | Irinotecan (CPT-11) | Irinotecan è un inibitore della topoisomerasi I per le cellule LoVo e HT-29 con IC50 di 15,8 μM e 5,17 μM, rispettivamente. |
|
|
| S1288 | Camptothecin (CPT) | Camptothecin (CPT) è un inibitore specifico della DNA topoisomerase I (Topo I) con un IC50 di 0,68 μM in un saggio senza cellule. Camptothecin induce l'apoptosis nelle cellule tumorali tramite vie mitocondriali mediate da microRNA-125b. Fase 2. |
|
|
| S1208 | Doxorubicin (Adriamycin) Hydrochloride | Doxorubicin (DOX) HCl è un agente antibiotico che inibisce la DNA topoisomerase II umana con IC50 di 2,67 μM. La Doxorubicin riduce la fosforilazione basale di AMPK. La Doxorubicin viene utilizzata nel trattamento concomitante di pazienti infetti da HIV ma si è scoperto che è ad alto rischio di riattivazione dell'HBV.Questo prodotto può precipitare quando disciolto in soluzione PBS. Si raccomanda di preparare la soluzione madre in acqua pura e diluire con acqua pura o soluzione fisiologica per ottenere la soluzione di lavoro.Doxorubicin (Adriamycin) HCl può essere utilizzato per indurre modelli animali di malattia renale. |
|
|
| S1225 | Etoposide | Etoposide è un derivato semisintetico della podofillotossina, che inibisce la sintesi del DNA tramite l'attività inibitoria della topoisomerase II che aumenta la scissione a doppio e singolo filamento del DNA e inibisce reversibilmente la riparazione mediante il legame della topoisomerase II. Etoposide induce autophagy, mitophagy e apoptosis. |
|
|
| S2492 | Novobiocin Sodium (Cathomycin, Albamycin) | Novobiocin Sodium (NSC 2382, Albamycin, Cathomycin) è un antibiotico aminocumarinico che bersaglia la DNA girasi (TopoIV) batterica, utilizzato per trattare batteri gram-positivi sensibili. |
|
|
| S4908 | SN-38 | SN-38 (NK012) è un metabolita attivo di CPT-11, inibisce la DNA topoisomerase I, la sintesi del DNA e causa frequenti rotture a singolo filamento del DNA. SN-38 induce l'autophagy. |
|
|
| S2217 | Irinotecan Hydrochloride Trihydrate | Irinotecan HCl Trihydrate è un triidrato di cloridrato di irinotecan (Camptosar, Campto, CPT-11) che è un inibitore della Topoisomerase I con IC50 di 15,8 e 5,17 μM rispettivamente per le cellule LoVo e le cellule HT-29. |
|
|
| S3035 | Daunorubicin Hydrochloride (Daunomycin) | Daunorubicin HCl inibisce sia la sintesi del DNA che dell'RNA e inibisce la sintesi del DNA con un Ki di 0,02 μM in un saggio senza cellule. La Daunorubicin è un inibitore della topoisomerase II che induce l'apoptosis.Il Daunorubicin (RP 13057) HCl può essere utilizzato per indurre modelli animali di malattia renale. |
|
|
| S1231 | Topotecan HCl | Topotecan HCl è un inibitore della topoisomerasi I per le cellule MCF-7 Luc e le cellule DU-145 Luc con IC50 di 13 nM e 2 nM in saggi acellulari, rispettivamente. Questo composto induce autophagy e apoptosis. |
|
|
DNA topoisomerases are nuclear enzymes that play a critical role in DNA transcription and replication events for the efficient creation and compaction of two identical genomes in two daughter cells. There are at least five different topoisomerase that have been found in higher eukaryotes that can be grouped into two categories: (1) type I family, includes topoisomerases I, IIIα, IIIβ, and (2) type II family, includes topoisomerases IIα and IIβ.[1][2]
Type I enzymes, which do not require ATP, cleave one DNA strand at a time to achieve DNA strand relaxation. More specifically, among type I family constituents, topoisomerase I-mediated DNA strand scission involves a nucleophilic attack by the active site tyrosine OH group on the DNA phosphodiester bond at the site of cleavage. Such an attack results in the breakage of the DNA phosphodiester backbone and the creation of a phosphotyrosine bond between the enzyme and DNA. This covalent binary complex DNA-topoisomerase I, the so-called cleavable complex, is typically only an intermediate. Relaxation via passage (swivel movement) of the broken DNA strand around the unbroken strand is followed by reformation of the phosphodiester backbone as a result of relegation, with concomitant release of topoisomerase I and enzyme turnover.[1][2]
In contrast, type II enzymes which are typically ATP-dependent are able to perform double strand cuts that relieve superhelical twists, intramolecular DNA knots, and intermolecular tangles for chromosomal segregation to produce a DNA-linked protein gate through which another intact duplex can pass. It should be emphasized that the enzyme shows strong preference for supercoiled DNA versus relaxed molecules. More specifically, with topoisomerase II enzymes it is observed that DNA cleavage occurs at preferred sequences within its recognition/binding sites, but there is not clear specificity.[1][2]
In either case, both types of topoisomerases cleave DNA at the phosphodiester backbone by nucleophilic attack from a catalytic tyrosine residue which becomes linked to the phosphate end (P-Y) of the DNA break. The reactions of both types of topoisomerases are highly reversible and leave the DNA sequence unchanged following topoisomerization.[1][2]
While both topoisomerases can relax supercoiled DNA, only topoisomerase II can decatenate DNA molecules. Interestingly, throughout the cell cycle topoisomerase I and topoisomerase IIβ do not change in concentration, meanwhile topoisomerase IIα protein level are noted to fluctuate in relation to the proliferative stage and cell cycle position. In particular, topoisomerase IIα mRNA peak in late S and G2/M several-fold over (typically more than 10 times) the amount observed in G1 cells. The high levels of topoisomerase IIα during the final stages of DNA replication is intended to assist with chromosome untangling, condensation and mitotic segregation events. Consequently, cancerous cells are noted to have high topoisomerase IIα activity, and these findings have prompted researchers to develop new anti-cancer agents that specifically target to poisomerase II.[1][2]
In general, topoisomerase I or topoisomerase II-directed anti-cancer agents are able to interfere with at least one step of the catalytic cycle of the enzyme. Among the topoisomerase I inhibitor class of compounds, Camptothecin (CPT) and its derivatives – a pentacyclic alkaloid formerly isolated as a natural extract from the Chinese tree Camptoteca acuminate – are effective at selectively targeting topoisomerase I by trapping its catalytic intermediate during the topoisomerase I-DNA reaction. Agents that effectively target topoisomerase II include the Anthracyclines (i.e. Adriamycin and Daunorubicin, 9 and 10), Epipodophyllotoxins (i.e. Etoposide and Teniposide 11 and 12), Antracendedione (i.e. Mitoxantrone, 13) and Aminoacrideines (i.e. m-AMSA). The compounds are successful at stabilizing the short-lived covalent complexes between topoisomerase II and DNA. The anti-cancer agents convert the topoisomerase II enzymes into DNA-cleaving toxins which are currently are area of research interest.[2]
I prodotti sono solo per uso di ricerca. Non per uso umano. Non vendiamo a pazienti.
©Copyright 2013 Selleck Chemicals. Tutti i diritti riservati.